This paper reported the results of a long-term subcutaneous immunoglobins (SCIg) treatment in a population of patients with chronic inflammatory demyelinating polyneuropathy (CIDP; n=17). Patients had a diagnosis of CIDP and were treated with intravenous (IV) immunoglobin every four to six weeks prior to being switched to SCIg. Patients were routinely assessed clinically. In the majority of pre-selected CIDP patients (n=16/17), SCIg were well tolerated and preferred over IV immunoglobin, according to the results. Additionally, strength and motor function were stable or improved during long-term follow-up (out to 84 months). There were also benefits for walking capability and resistance, manual activity performances, and fatigue reduction. “Patient perception of treatment is very positive, with SCIg clearly preferred to IV immunoglobin as a chronic treatment,” the authors wrote. “These results strengthen the recommendation to use SCIg as a very good choice as chronic therapy in CIDP patient IV immunoglobin responders.”